Allergy Therapeutics
To see an up-to date selection of historical analyses and insights on
Allergy Therapeutics,
visit our
new, dynamically updated Company Summary report pages for Allergy Therapeutics.
As a Guest User, you will have FREE access to a selection of historical analyses
and insights from EvaluatePharma®.
How to access FREE content
- Search the content using the search box at the top of every page
- Browse content by Company, Product, Generic Name, Therapeutic Category or Indication using the "Browse By" link from the navigation bar
- Create Peer Groups to compare Companies using the "Peer Groups" link from the navigation bar
Register for FREE to access even more content including 2007
Product Sales and Rankings.
A small selected sample of reports and related news headlines for
Allergy Therapeutics are available below.
Free sample reports are also available for other Companies.
To find out how you can access more detailed information on
Allergy Therapeutics,
or on any other Company covered by EvaluatePharma® Contact Us today.
CONSENSUS FORECASTS ($US mln) - Sales Forecasts available to EvaluatePharma Subscribers
|
|
|
Annual Sales WW - Sales |
Growth per Year (%) |
|
|
Rank |
Product |
Generic Name |
Pharmacological Class |
2006 |
2007 |
2007 |
| Allergy Therapeutics |
1 |
Pollinex Quattro |
- |
Allergy vaccine |
18 |
24 |
|
30% |
|
|
|
2 |
Tyrosine TU t.o.p |
- |
Anti-allergy agent |
9 |
11 |
|
14% |
|
|
|
3 |
Oralvac/Oralvac Plus |
- |
Allergy vaccine |
9 |
10 |
|
20% |
|
|
|
|
|
Note: Shaded Cells |
|
|
|
|
PIPELINE ANALYSIS - Sales Forecasts available to EvaluatePharma Subscribers
|
|
|
|
|
Rank |
Product |
Therapeutic Category |
Therapeutic Subcategory |
Pharmacological Class |
Phase (Current) |
| Allergy Therapeutics |
- |
Pollinex Quattro Grass |
Respiratory |
Other respiratory agents |
Allergy vaccine |
Phase III |
|
|
- |
Pollinex Quattro Ragweed |
Respiratory |
Other respiratory agents |
Allergy vaccine |
Phase III |
|
|
- |
Pollinex Quattro Japanese Cedar |
Respiratory |
Other respiratory agents |
Allergy vaccine |
Pre-clinical |
|
|
|
FINANCIAL DATA ($US mln) - Forecasts available to EvaluatePharma Subscribers
|
| Allergy Therapeutics |
|
|
2005 |
2006 |
| Valuation Measures |
| Based on Latest Share Prices |
| Valuing the Equity |
| Market Capitalisation |
10 |
10 |
| PE Ratio (diluted) - Normalised (x) |
(0.8) |
(0.2) |
|
|
| Valuing the Enterprise |
| Enterprise Value |
46 |
46 |
| Free Cash Flow (Pre-Dividends) |
(17) |
(41) |
| FCF Yield (%) |
(37.3%) |
(88.7%) |
|
|
| Forecast Financials |
| Income Statement |
| Total Revenues |
42 |
50 |
| Cost of Goods Sold |
(12) |
(19) |
| S,G & A |
(26) |
(32) |
| R&D |
(17) |
(49) |
| Other Income/ Expense - Net |
0 |
0 |
| EBIT - Normalised |
(12) |
(51) |
| Net Interest & Financial Items |
1 |
1 |
| Pre-tax Profits - Normalised |
(11) |
(50) |
| Income Before Taxes |
(11) |
(50) |
| Tax |
0 |
5 |
| Tax Rate (%) |
0.0% |
9.7% |
| Net Income - Reported |
(11) |
(45) |
| Net Income - Normalised |
(11) |
(45) |
|
|
| Per Share Data |
| EPS - Diluted |
(0.17) |
(0.55) |
| EPS - Basic |
(0.17) |
(0.55) |
| EPS - Normalised (diluted) |
(0.17) |
(0.55) |
| EPS - Normalised (basic) |
(0.17) |
(0.55) |
| Avg. Shares Outstanding - Diluted |
66.1 |
82.0 |
| Avg. Shares Outstanding - Basic |
66.1 |
82.0 |
| DPS |
0.00 |
0.00 |
|
|
|
NEWS - Selected Product News Headlines (as of 11 June 2008)
|
| Pivotal Phase III Pollinex® Quattro Ragweed Study Meets Primary Efficacy Endpoint
|
(Allergy Therapeutics)
|
22-Sep-2008 |
| Pollinex® Quattro Data Presented at European Academy of Allergology and Clinical Immunology Meeting
|
(Allergy Therapeutics)
|
09-Jun-2008 |
| Allergy Therapeutics scores crucial goal
|
(Allergy Therapeutics)
|
14-May-2008 |
| Pivotal Phase III Pollinex® Quattro Grass Study Meets Primary Efficacy Endpoint
|
(Allergy Therapeutics)
|
14-May-2008 |
| EP Vantage Interview - Allergy Therapeutics phase III data could lift gloom
|
(Allergy Therapeutics)
|
17-Mar-2008 |
|
|
|
IN-DEPTH COMPETITIVE INTELLIGENCE AVAILABLE ON
|
|
|
|
|
Product |
Generic Name |
| Allergy Therapeutics |
Alavac House Dust Mite |
- |
|
|
Oralvac/Oralvac Plus |
- |
|
|
Pollinex Grasses & Rye |
- |
|
|
Pollinex Quattro |
- |
|
|
Pollinex Quattro Grass |
- |
|
|
Pollinex Quattro Japanese Cedar |
- |
|
|
Pollinex Quattro Mite |
- |
|
|
Pollinex Quattro Ragweed |
- |
|
|
Pollinex Quattro Tree |
- |
|
|
Pollinex R (Ragweed) |
- |
|
|
Pollinex Tree |
- |
|
|
Sublingual MPL Vaccine |
- |
|
|
Tyrosine TU t.o.p |
- |
|
|
Venomil Bee & Wasp |
- |
|
|
Zaditen Optha |
ketotifen fumarate |
|
|
|
EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx
(prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings,
annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts
for marketed and emerging products are built-up using recent research reports from top equity analysts.
Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I,
phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy,
patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates,
deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age -
plus many more data items and analytics unique to EvaluatePharma®.
Aggregations of these measures at a high-level means that companies may be ranked against each other on items
such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs
organic sales), sales by therapy area or technology and various other concentration measures. These
aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis.
Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available
Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.
